



Data from the phase 3 SIERRA trial of lomab-B presented at the annual European Association of Nuclear Medicine (EANM) Congress 2024

Stockholm, October 25, 2024 – Immedica is pleased to announce that data from the Phase 3 SIERRA trial of lomab-B was presented in both an oral and a poster presentation at the 2024 European Association of Nuclear Medicine (EANM) Congress, held in Hamburg from October 19-23. Immedica is collaborating with Actinium Pharmaceuticals on the development of lomab-B.

Dr. Neeta Pandit-Taskar, Molecular Imaging and Therapy, Memorial Sloan Kettering Cancer Center, New York, U.S. presented the results:

Details of the EANM oral presentation:

Title (OP-097): “Modeling-based Assessment of Exposure Measurements After High-Dose Targeted 131I-apamistamab: Results and Analyses from the Phase III SIERRA Trial”

Session: Cutting Edge Science Track - Featured Session: Radiation Protection Committee / EARL: Radiation Protection for Radionuclide Therapy and Animal Protection

Date and Time: October 20, 2024, 09:45 – 11:15 (CET), Hall Y4-Y9

Details of the EANM e-poster presentation:

Title (EPS-134): Bone Marrow Dosimetry Exploratory Analysis from the Phase 3 SIERRA Trial of 131I-apamistamab Prior to HCT in Relapsed/Refractory Acute Myeloid Leukemia

Session: e-Poster Presentations Session 7: Dosimetry Committee: Evolving Dosimetry Strategies

Date and time: October 21, 2024, 15:00 – 16:30 (CET), Hall F.

About EANM meeting

The EANM Annual Meeting is the premier event for professionals in the field of nuclear medicine, bringing together experts from around the world to discuss the latest advancements, research, and innovations. The meeting provides a platform for sharing knowledge, fostering collaboration, and exploring new developments in diagnostic imaging, radionuclide therapies, and molecular medicine.

About Actinium Pharmaceuticals, Inc.

Actinium develops targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies. Advanced pipeline candidate lomab-B is an induction and conditioning agent prior to bone marrow transplant. Actinium holds more than 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.

For more information, please visit: <http://www.actiniumpharma.com/>

About Immedica

Immedica is a pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Immedica's capabilities cover marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory, medical affairs and market access, as well as a global distribution network serving patients in more than 50 countries. Immedica is fully dedicated to helping those living with diseases which have a large unmet medical need. Immedica's therapeutic areas are within genetic & metabolic diseases, hematology & oncology and specialty care.

Immedica was founded in 2018 and employs today more than 140 people across Europe, the Middle East and the U.S. The main owners are the investment firms KKR and Impilo.

For more information visit www.immedica.com

Immedica contact:

Linda Holmström

Head of Communication

linda.holmstrom@immedica.com

+ 46 708 73 40 95